188Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: A phase I safety and toxicity study

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 9, 2009, Pages 1425-1433

  Lam, Marnix G E H ^a   Bosma, Tjitske B ^a   Van Rijk, Peter P ^a   Zonnenberg, Bernard A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bone metastases; Capecitabine; Nuclear therapy; Phase I; Rhenium

Indexed keywords

CAPECITABINE; HYDROXYETHYLIDENEDIPHOSPHONATE RE 188; RHENIUM 188; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED STUDY; COR PULMONALE; DIARRHEA; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; INTERNATIONAL NORMALIZED RATIO; LEUKOPENIA; NAUSEA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PROSTATE CANCER; SIDE EFFECT; STOMATITIS; THIN LAYER CHROMATOGRAPHY; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; ETIDRONIC ACID; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RHENIUM;

EID: 68949211185     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1119-8     Document Type: Article

References (32)

1. DR Berthold CN Sternberg IF Tannock 2005 Management of advanced prostate cancer after first-line chemotherapy J Clin Oncol 23 8247 8252
2. MG Lam JM de Klerk PP van Rijk BA Zonnenberg 2007 Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases Anticancer Agents Med Chem 7 381 397
3. S Ricci G Boni I Pastina D Genovesi C Cianci S Chiacchio, et al 2007 Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer Eur J Nucl Med Mol Imaging 34 1023 1030
4. R Sciuto A Festa S Rea R Pasqualoni S Bergomi G Petrilli, et al 2002 Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial J Nucl Med 43 79 86
5. SM Tu RE Millikan B Mengistu ES Delpassand RJ Amato LC Pagliaro, et al 2001 Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial Lancet 357 336 341
6. MG Lam BA Zonnenberg 2008 Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases Eur J Nucl Med Mol Imaging 35 1394 1395
7. WY Lin CP Lin SJ Yeh BT Hsieh ZT Tsai G Ting, et al 1997 Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases Eur J Nucl Med 24 590 595
8. HR Maxon III LE Schroder LC Washburn SR Thomas RC Samaratunga D Biniakiewicz, et al 1998 Rhenium-188(Sn)HEDP for treatment of osseous metastases J Nucl Med 39 659 663
9. S Li J Liu H Zhang M Tian J Wang X Zheng 2001 Rhenium-188 HEDP to treat painful bone metastases Clin Nucl Med 26 919 922
10. K Liepe J Kropp R Runge J Kotzerke 2003 Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases Br J Cancer 89 625 629
11. H Palmedo A Manka-Waluch P Albers IG Schmidt-Wolf M Reinhardt S Ezziddin, et al 2003 Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate J Clin Oncol 21 2869 2875
12. H Zhang M Tian S Li J Liu S Tanada K Endo 2003 Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients Cancer Biother Radiopharm 18 719 726
13. AJ Wagstaff T Ibbotson KL Goa 2003 Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer Drugs 63 217 236
14. CM Walko C Lindley 2005 Capecitabine: a review Clin Ther 27 23 44
15. A Patel A Puthillath G Yang MG Fakih 2008 Neoadjuvant chemoradiation for rectal cancer: is more better? Oncology (Williston Park) 22 814 826
16. MM Corsini RC Miller MG Haddock JH Donohue MB Farnell DM Nagorney, et al 2008 Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005) J Clin Oncol 26 3511 3516
17. TA Rich RC Shepard ST Mosley 2004 Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy J Clin Oncol 22 2214 2232
18. S Touffet G Gayet S Samperez P Jouan 1992 Demonstration of thymidine phosphorylase activity in human healthy, adenomatous and cancerous prostate (in French) Bull Cancer 79 151 159
19. E Sivridis A Giatromanolaki I Papadopoulos KC Gatter AL Harris MI Koukourakis 2002 Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis Br J Cancer 86 1465 1471
20. E Ben-Josef 2007 Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer Am J Clin Oncol 30 649 655
21. GM Blake MA Zivanovic AJ McEwan DM Ackery 1986 Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate Eur J Nucl Med 12 447 454
22. H Palmedo S Guhlke H Bender J Sartor G Schoeneich J Risse, et al 2000 Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases Eur J Nucl Med 27 123 130
23. K Liepe R Hliscs J Kropp R Runge FF Knapp Jr WG Franke 2003 Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases J Nucl Med 44 953 960
24. H Ishitsuka 2000 Capecitabine: preclinical pharmacology studies Invest New Drugs 18 343 354
25. BF El Rayes CA Black JF Ensley 2003 Hormone-refractory prostate cancer responding to capecitabine Urology 61 462
26. R Morant J Bernhard D Dietrich S Gillessen M Bonomo M Borner, et al 2004 Capecitabine in hormone-resistant metastatic prostatic carcinoma-a phase II trial Br J Cancer 90 1312 1317
27. J Spicer T Plunkett N Somaiah S Chan A Kendall N Bolunwu, et al 2005 Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer Prostate Cancer Prostatic Dis 8 364 368
28. IF Tannock R de Wit WR Berry J Horti A Pluzanska KN Chi, et al 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502 1512
29. N Sawada T Ishikawa Y Fukase M Nishida T Yoshikubo H Ishitsuka 1998 Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts Clin Cancer Res 4 1013 1019
30. JL Fischel JM Ferrero P Formento J Ciccolini N Renee JL Formento, et al 2005 Taxotere-5′-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells Anticancer Drugs 16 309 316
31. JM Ferrero E Chamorey S Oudard S Dides G Lesbats G Cavaglione, et al 2006 Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer Cancer 107 738 745
32. M Kolodziej MA Neubauer SR Rousey RE Pluenneke G Perrine S Mull, et al 2006 Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer Clin Genitourin Cancer 5 155 161